These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 21417065

  • 1. Ineffectiveness of prophylactic epsilon aminocaproic acid in severe hemophilia.
    STRAUSS HS, KEVY SV, DIAMOND LK.
    N Engl J Med; 1965 Aug 05; 273(6):301-4. PubMed ID: 21417065
    [No Abstract] [Full Text] [Related]

  • 2. Epsilon aminocaproic acid.
    N Engl J Med; 1965 Aug 05; 273(6):336-7. PubMed ID: 21417074
    [No Abstract] [Full Text] [Related]

  • 3. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    van Galen KP, Engelen ET, Mauser-Bunschoten EP, van Es RJ, Schutgens RE.
    Cochrane Database Syst Rev; 2015 Dec 24; (12):CD011385. PubMed ID: 26704192
    [Abstract] [Full Text] [Related]

  • 4. [The application of epsilon-aminocaproic acid in the treatment of hemophilia].
    Gugler E, Käser H, Bütler R.
    Schweiz Med Wochenschr; 1966 Mar 26; 96(12):386-93. PubMed ID: 5984001
    [No Abstract] [Full Text] [Related]

  • 5. Danazol in hemophilia.
    Ambriz R, Pizzuto J, Guillen C.
    JAMA; 1985 Aug 09; 254(6):754-5. PubMed ID: 4009909
    [No Abstract] [Full Text] [Related]

  • 6. Oral bleeding in hemophilia: treatment with epsilon aminocaproic acid and replacement therapy.
    Corrigan JJ.
    J Pediatr; 1972 Jan 09; 80(1):124-8. PubMed ID: 4536942
    [No Abstract] [Full Text] [Related]

  • 7. Current issues in prophylactic therapy for persons with hemophilia.
    Dunn AL, Abshire TC.
    Acta Haematol; 2006 Jan 09; 115(3-4):162-71. PubMed ID: 16549891
    [Abstract] [Full Text] [Related]

  • 8. An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia.
    Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L, Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and Participating Survey Investigators.
    Haemophilia; 2017 Sep 09; 23(5):e444-e447. PubMed ID: 28439934
    [No Abstract] [Full Text] [Related]

  • 9. Epsilon aminocaproic acid in hemophiliacs undergoing dental extractions: a concise review.
    Lucas ON, Albert TW.
    Oral Surg Oral Med Oral Pathol; 1981 Feb 09; 51(2):115-20. PubMed ID: 6782532
    [Abstract] [Full Text] [Related]

  • 10. Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial.
    Walsh PN, Rizza CR, Matthews JM, Eipe J, Kernoff PB, Coles MD, Bloom AL, Kaufman BM, Beck P, Hanan CM, Biggs R.
    Br J Haematol; 1971 May 09; 20(5):463-75. PubMed ID: 4931484
    [No Abstract] [Full Text] [Related]

  • 11. Acute myocardial infarction in a young hemophiliac patient during therapy with Factor IX concentrate and epsilon aminocaproic acid.
    Agrawal BL, Zelkowitz L, Hletko P.
    J Pediatr; 1981 Jun 09; 98(6):931-3. PubMed ID: 7229796
    [No Abstract] [Full Text] [Related]

  • 12. The use of epsilon-aminocaproic acid for the management of hemophilia in dental and oral surgery patients.
    Evans BE.
    J Am Dent Assoc; 1977 Jan 09; 94(1):21. PubMed ID: 264310
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacoeconomic impact of obesity in severe haemophilia children on clotting factor prophylaxis in a single institution.
    Majumdar S, Ostrenga A, Latzman RD, Payne C, Hunt Q, Morris A, Iyer R.
    Haemophilia; 2011 Jul 09; 17(4):717-8. PubMed ID: 21323798
    [No Abstract] [Full Text] [Related]

  • 14. Hemophilia. Current concepts in management.
    Green D, Smith NJ.
    Med Clin North Am; 1972 Jan 09; 56(1):105-17. PubMed ID: 4550184
    [No Abstract] [Full Text] [Related]

  • 15. Insufficient evidence to suggest less stringent therapy in hemophilia B?
    den Uijl IE, Roosendaal G, Fischer K.
    Blood; 2009 Nov 26; 114(23):4907; author reply 4907-8. PubMed ID: 19965698
    [No Abstract] [Full Text] [Related]

  • 16. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia.
    van den Berg HM, Fischer K, Mauser-Bunschoten EP, Beek FJ, Roosendaal G, van der Bom JG, Nieuwenhuis HK.
    Br J Haematol; 2001 Mar 26; 112(3):561-5. PubMed ID: 11260054
    [Abstract] [Full Text] [Related]

  • 17. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations.
    Perry D, Berntorp E, Tait C, Dolan G, Holme PA, Laffan M, Lassila R, Mumford A, Pasi J, Wilde J, Will A, Yee TT.
    Haemophilia; 2010 Jan 26; 16(1):80-9. PubMed ID: 19780845
    [Abstract] [Full Text] [Related]

  • 18. Individualizing primary prophylaxis in patients with hemophilia A and B, adherence and new products.
    Berrueco R.
    Blood Coagul Fibrinolysis; 2023 Jun 01; 34(S1):S12-S14. PubMed ID: 37254724
    [Abstract] [Full Text] [Related]

  • 19. [Outpatient care of hemophilia patients].
    Fedorova ZD, Levina OA, Kotovshchikova MA, Abramov VS.
    Vestn Khir Im I I Grek; 1967 Mar 01; 98(3):115-9. PubMed ID: 5609126
    [No Abstract] [Full Text] [Related]

  • 20. [Therapy and prophylaxis of hemorrhage in hemophilia].
    Koller F.
    Schweiz Med Wochenschr; 1972 Jun 10; 102(23):810-4. PubMed ID: 4537548
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.